Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing four products, including AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia; and AT982 for the treatment of pompe disease. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, an inherited, metabolic liver disease. The company was founded in 2012 and is based in San Francisco, California.